Top 50 Biotech Startup Investors in France (September 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Bpifrance
VC Fund
|
127 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $757k–$34M |
|
Seventure Partners
VC Fund
|
35 | France, United States, Germany | Series A, Series B | Biotechnology, Health Care, Software | $3.2M–$63M |
|
Kurma Partners
VC Fund
|
34 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.7M–$98M |
|
Sofinnova Partners
VC Fund
|
29 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
GO CAPITAL
VC Fund
|
29 | France, Canada, Israel | Seed, Venture - Series Unknown, Series A | Software, Biotechnology, Health Care | $549k–$13M |
|
Karista
VC Fund
|
25 | France, United States, Finland | Seed, Series A, Series B | Software, Biotechnology, Health Care | $768k–$33M |
|
Elaia
VC Fund
|
22 | France, United States, Spain | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.1M–$50M |
|
Idinvest Partners
VC Fund
|
21 | France, United States, Germany | Series A, Series B, Venture - Series Unknown | Software, Health Care, Biotechnology | $3.9M–$66M |
|
Omnes Capital
VC Fund
|
18 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $4.3M–$53M |
|
Auriga Partners
VC Fund
|
18 | France, United States, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $2.2M–$33M |
|
Angels Santé
VC Fund
|
16 | France, India, United States | Seed, Venture - Series Unknown, Angel | Health Care, Biotechnology, Medical Device | $664k–$8.2M |
|
Entrepreneurs First
VC Fund
|
15 | United Kingdom, United States, India | Pre-Seed, Seed, Series A | Artificial Intelligence, Software, Information Technology | $54k–$41M |
|
AdBio partners
VC Fund
|
13 | France, Spain, Belgium | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Pharmaceutical | $2.2M–$37M |
|
Eurazeo
VC Fund
|
12 | France, United States, Germany | Series B, Seed | Software, Information Technology, Health Care | $3.2M–$125M |
|
Sofimac Investment Managers
VC Fund
|
12 | France, Italy, Austria | Seed, Venture - Series Unknown | Biotechnology, Health Care, Manufacturing | $268k–$8M |
|
Pontifax
VC Fund
|
11 | United States, Israel, France | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.3M–$130M |
|
Crédit Agricole
VC Fund
|
11 | France, United States, Italy | Debt Financing, Seed | Energy, Health Care, Software | $837k–$1.3B |
|
AQUITI Gestion
VC Fund
|
11 | France, United States | Venture - Series Unknown, Series A, Seed | Software, Biotechnology, Manufacturing | $170k–$18M |
|
IRDI SORIDEC Gestion
VC Fund
|
10 | France, Brazil, Singapore | Seed, Series A, Venture - Series Unknown | Software, Biotechnology, Medical | $1.3M–$13M |
|
WiSEED
VC Fund
|
10 | France, Norway | Seed, Venture - Series Unknown, Series A | Software, Biotechnology, Manufacturing | $392k–$7.8M |
|
Inserm Transfert Initiative
VC Fund
|
9 | France, Switzerland, United States | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.1M–$60M |
|
BNP Paribas Développement
VC Fund
|
9 | France, Germany, The Netherlands | Series A, Seed | Software, Health Care, Information Technology | $2M–$24M |
|
BNP Paribas
VC Fund
|
9 | France, United Kingdom, United States | Debt Financing, Post-IPO Debt | Financial Services, Information Technology, Software | $8.5M–$2.5B |
|
Kima Ventures
VC Fund
|
9 | France, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, SaaS | $591k–$16M |
|
Cap Innov'Est
VC Fund
|
9 | France, United States | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Medical | $706k–$8.3M |
|
UI Investissement
VC Fund
|
8 | France, Spain, Canada | Private Equity, Seed, Series A | Manufacturing, Software, Health Care | $1.5M–$49M |
|
XAnge
VC Fund
|
8 | France, Germany, Belgium | Series A, Seed, Series B | Software, SaaS, E-Commerce | $1.1M–$75M |
|
Octalfa
VC Fund
|
8 | France | Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $658k–$4.6M |
|
Demeter
VC Fund
|
8 | France, Germany, Slovenia | Seed, Series A | Manufacturing, Software, AgTech | $1.5M–$27M |
|
Galia Gestion
VC Fund
|
8 | France, United States | Venture - Series Unknown, Series A | Software, Manufacturing, Biotechnology | $849k–$12M |
|
IRDI
VC Fund
|
8 | France | Series A, Seed | Health Care, Software, Biotechnology | $757k–$23M |
|
Anaxago
VC Fund
|
8 | France, Belgium, Cameroon | Seed, Series A, Venture - Series Unknown | Biotechnology, SaaS, Software | $620k–$13M |
|
Meusinvest (Noshaq)
VC Fund
|
8 | Belgium, France, Germany | Series A, Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $137k–$16M |
|
Starquest Capital
VC Fund
|
7 | France, Singapore, United States | Seed, Venture - Series Unknown, Series A | Software, Manufacturing, Information Technology | $291k–$20M |
|
Caisse d’Epargne
VC Fund
|
7 | France | Debt Financing, Seed | Software, Health Care, Biotechnology | $400k–$169M |
|
Finovam Gestion
VC Fund
|
7 | France, United States | Seed, Series A | Software, Information Technology, Medical | $513k–$18M |
|
Sham Innovation Santé
VC Fund
|
7 | France | Series B, Series A, Venture - Series Unknown | Biotechnology, Medical Device, Medical | $1.8M–$80M |
|
SOSV
VC Fund
|
6 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
InnoBio Fund
VC Fund
|
6 | France, United States | Series A, Series B, Series C | Biotechnology, Therapeutics, Pharmaceutical | $14M–$26M |
|
Pureos Bioventures
VC Fund
|
6 | France, Switzerland, United States | Series A, Series B, Series C | Biotechnology, Therapeutics, Medical | $7.1M–$125M |
|
M Capital Partners
VC Fund
|
6 | France, United States, Canada | Venture - Series Unknown, Seed | Health Care, Software, Food and Beverage | $1.1M–$5.6M |
|
Crédit Mutuel Innovation
VC Fund
|
6 | France, United States, Belgium | Series A, Series B | Software, Health Care, Biotechnology | $3.4M–$43M |
|
Emertec
VC Fund
|
6 | France, Canada, Switzerland | Series A, Venture - Series Unknown, Seed | Electronics, Energy, Biotechnology | $1.2M–$6.8M |
|
CEA Investissement
VC Fund
|
6 | France, Canada, United States | Seed, Series A | Manufacturing, Energy, Biotechnology | $796k–$21M |
|
Paca Investissement
VC Fund
|
6 | France | Seed, Venture - Series Unknown | Software, Internet, Manufacturing | $325k–$5.7M |
|
Verve Ventures
VC Fund
|
6 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.2M–$45M |
|
Nord France Amorcage
VC Fund
|
5 | France, United States | Seed, Venture - Series Unknown, Series A | Software, Health Care, Information Technology | $421k–$25M |
|
Andera Partners
VC Fund
|
5 | France, United States, Germany | Series B, Private Equity, Series A | Biotechnology, Health Care, Medical | $7M–$237M |
|
Newfund
VC Fund
|
5 | France, United States, Canada | Seed, Series A | Software, Information Technology, SaaS | $1.1M–$15M |
|
HCVC
VC Fund
|
5 | United States, France, United Kingdom | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Robotics | $920k–$30M |
| Access all 1265 investors in France Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1680
- Round size: Seed $757k–$6.1M; Series A $2.8M–$34M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $27M in 2025
Portfolio highlights
- Nepsis — AI-powered software and debt advisory for renewable energy developers. Modern financing solutions for small & medium renewable projects.
- Hiqute Diamond — High quality diamond plates for high-end applications
- Tribun Health — Tribun Health provides a complete digital pathology platform for diagnosis, prognosis and biomarker analysis.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 265
- Round size: Series A $3.2M–$28M; Series B $3.4M–$63M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Presto Engineering — We enable companies imagine and implement microelectronics solutions in high-value markets such as Industrial, Automotive, Communication and Medical.
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 145
- Round size: Seed $2.7M–$14M; Series A $3.9M–$98M; Series B $12M–$72M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely actively investing — fresh fund, raised $236M in 2024
Portfolio highlights
- EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
- Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 350
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, Canada, Israel
Investor stats
- Total investments: 141
- Round size: Seed $549k–$7.1M; Series A $2.1M–$13M; Venture - Series Unknown $723k–$9.5M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $25M in 2023
Portfolio highlights
- Axomove — Axomove specializes in the prescription of video-based physical exercises. The company's movement knowledge is used by health professionals to improve remote monitoring of their patients and to avoid Musculoskeletal Disorders (MSDs) at work.
- Olenbee — Olenbee develops fintech solutions that connect employee benefits directly to everyday card spending. The company offers a mobile application and employer platform that link meal vouchers, gift vouchers and other planned benefits to employees’ usual bank cards and accounts. Its title-restaurant product Olenfood allows food-related expenses to beidentified from card transactions and reimbursed in line with regulation. The Olengift service applies the same principle to gift vouchers without dedicated cards or closed merchant networks. Olenbee also works on additional benefit lines such as culture, sustainable mobility, sport, holidays and home office support. Its infrastructure is designed to handle eligibility rules and integrate with HR and payroll processes for employers, while providing dedicated spaces for merchants and employees.
- NeoXperiences — NeoXperiences develops technological solutions that bring audiences together around fun and interactive experiences.
Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: France, United States, Finland
Investor stats
- Total investments: 159
- Round size: Seed $768k–$6.2M; Series A $1.4M–$23M; Series B $2.5M–$33M
- Lead/follow: 18% lead, 82% follow
- Last fund: Likely still investing — raised $44M in 2021
Portfolio highlights
- AlephD — The programmatic performance company
- Playtem — Playtem is a team led by passionate entrepreneurs. Their goal is to create the future of advertising thanks to their new in-game native formats. They believe that having an impactful format for the brands while maintaining an optimal user experience is possible.
- Plasmabiotics — PENTAX Medical PlasmaBiotics: Ultra-fast endoscope reprocessing solutions to improve patient safety and infection prevention.
Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: France, United States, Spain
Investor stats
- Total investments: 237
- Round size: Seed $1.1M–$7.6M; Series A $2.7M–$23M; Series B $4.2M–$50M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely actively investing — fresh fund, raised $154M in 2026
Portfolio highlights
- Hema.to — Flow cytometry analysis software, re-imagined. From raw FCS and LMD data to finalized report with AI-powered CellStudio.
- Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
- Sim&Cure — Providing Physicians with advanced endovascular treatment solutions for a better Patient Care
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: France, United States, Germany
Investor stats
- Total investments: 338
- Round size: Series A $3.9M–$22M; Series B $7.8M–$66M; Venture - Series Unknown $4.1M–$65M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $97M in 2021
Portfolio highlights
- Actility — Actility provides IoT connectivity and solutions to power smart cities and industries.
- Pretty Simple — Video games studio based in Paris, France. Makers of Criminal Case and Sorcery School.
- StarTower — StarTower is a resource company built specifically for fully decentralized physical infrastructure and shared interaction. Based on the exclusive RIP encryption technology, StarTower realizes the interactive sharing of multiple resources with zero loss on mobile devices, thereby providing efficient resource transmission for terminal facilities. Itprovides more efficient, secure and reliable solutions in the fields of Internet of Things, smart cities, industrial automation, healthcare, etc.
Omnes Capital takes a unique approach to renewable energy, transforming developers into independent power producers to provide green energy to millions.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 185
- Round size: Series A $4.3M–$41M; Series B $4.4M–$53M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely actively investing — fresh fund, raised $132M in 2025
Portfolio highlights
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- Adictiz — Adictiz, a French company founded in 2009 by Charles Christory, develops and publishes social games for the web and mobile phones.With successful brands including “Space Dog” and “What a Stupid Pigeon”, which attract close to 2.5 million players every month, Adictiz has established itself as an expert player in social and mobile gaming.Basedat the EuraTechnologies economic excellence hub in Lille, which is dedicated to serving information and communication technology companies, Adictiz set up Adictiz Studio in late 2011, which specialises in the creation of customised social games for brands. Adictiz Studio was recently selected by Facebook as a PMD (Preferred Marketing Developer).
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 128
- Round size: Series A $2.2M–$14M; Series B $3.8M–$33M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — raised $57M in 2013
Portfolio highlights
- Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
- Bonitasoft — Bonita helps businesses automate workflows, boost efficiency, and turn complexity into a competitive edge. Unlock the power of process automation today!
- Median Technologies — We harness the power of Imaging Phenomics to contribute to the development of next generation treatments and care strategies for patients in need.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Angels Santé is the leading French Business Angel Network solely dedicated to Healthcare investments.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Venture - Series Unknown, Angel
- Geography: France, India, United States
Investor stats
- Total investments: 37
- Round size: Seed $1.1M–$4.6M; Angel $687k–$1.3M; Venture - Series Unknown $664k–$8.2M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Kimialys — Kimialys provides a patented and disruptive surface chemistry for biosensors, enabling the development of innovative rapid diagnostic assays.
- StemInov — StemInov is developing a stem cell therapy for inflammatory diseases with a first focus on critical care: septic shock and ARDS
- SeaBeLife — SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.
We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 478
- Round size: Seed $54k–$6.5M; Pre-Seed $55k–$2.7M; Series A $5.1M–$41M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fresh fund, raised $133M in 2026
Portfolio highlights
- Sourcepulse — Your early warning system for software delivery (YC S23)
- Open Cosmos — Open Cosmos design, build and operate space missions, providing straightforward access to high quality satellite data and insights on a global scale.
- HelmGuard AI — HelmGuard develops an AI-driven trust infrastructure platform for security, compliance, and third-party risk management. The company provides an operational risk infrastructure layer that centralizes fragmented security, compliance, and vendor data into a structured repository. Its platform coordinates autonomous, domain-specific AI agents thatperform continuous data indexing, compliance mapping, automated vendor assessments, and real-time security tracking. HelmGuard includes a risk operating system, a zero-knowledge verification engine for selective disclosure and cryptographic-style proofs, and persona-specific risk intelligence reporting. These capabilities support first-party, third-party, and customer-facing workflows across sectors such as financial services, SaaS, and healthcare. The platform is used by security, risk, and compliance teams to maintain continuous oversight of internal controls, vendor posture, and regulatory obligations while generating tailored, natural-language reports for business stakeholders.
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, Spain, Belgium
Investor stats
- Total investments: 32
- Round size: Seed $2.2M–$18M; Series A $18M–$37M; Venture - Series Unknown $2.2M–$16M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $116M in 2021
Portfolio highlights
- Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
- ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Eurazeo is a private equity and venture capital firm that invests in SMEs and manages a diversified portfolio of assets.With its expertise in private equity, real estate, and private debt, the group supports companies of all sizes in their development commitment through the commitment of its 235 professionals. It provides companies with thenecessary investments needed to realize their growth potential.The firm was founded in 1969 and is based in Paris, Ile-de-France, France.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series B, Seed
- Geography: France, United States, Germany
Investor stats
- Total investments: 377
- Round size: Seed $3.2M–$16M; Series B $17M–$125M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely actively investing — fresh fund, raised $2.6B in 2026
Portfolio highlights
- Proteor — Proteor offers a complete range of high quality products and services to the O&P world, through more than 60 clinics.
- Kota — Replace your tools, brokers and outdated processes with the only platform that handles the entire employee benefits journey.
- Celcius Logistics Solutions — India's Largest 'ONLINE " cold chain network.Book reefer vehicles, Cold Storages or get booking for your vehicle and cold storages across India instantly with the best price
Acteur incontournable du capital risque de proximité, SOFIMAC PARTNERS accompagne depuis maintenant plus de 30 ans les PME régionales dans le financement de leur développement à moyen / long terme. Répondant à la problématique de sous capitalisation des PME françaises, SOFIMAC PARTNERS intervient en fonds propres aux côtés des chefsd’entreprises quelle que soit leur problématique : Création, Développement, Transmission. Gérant 200 M€ d’actifs au travers de 16 fonds (FCPR, FCPI, SCR, FIP,…), notre groupe réalise ses investissements sur une grande variété de secteurs, couvrant aussi bien les activités traditionnelles que technologiques (chimie verte, éolien, chaudronnerie aéronautique, e-commerce, édition de logiciel, médecine nucléaire etc…)
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Seed, Venture - Series Unknown
- Geography: France, Italy, Austria
Investor stats
- Total investments: 74
- Round size: Seed $268k–$3.1M; Venture - Series Unknown $556k–$8M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Ultrawatt — Ultrawatt is a mission-driven startup to improve urban architecture while making a beneficial social and environmental effect.
- Mob-Energy — Mob-Energy is a privately held company specializing in the development of mobile and innovative charging solutions. It designs autonomous charging robots capable of moving energy where it is needed, optimizing the site's existing infrastructure. The company was founded in 2018 and is headquartered in Villeurbanne, Auvergne-Rhône-Alpes.
- Snowleader — Votre boutique en ligne (qui sent bon le reblochon) spécialiste des sports d’hiver, outdoor et street.
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 122
- Round size: Series A $6.3M–$110M; Series B $20M–$130M; Series C $22M–$101M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $14M in 2020
Portfolio highlights
- Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
- Crystalys Therapeutics — Transforming care for people living with gout.
- Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
Credit Agricole is a banking corporation with focuses on corporate and investment banking, retail banking, and savings management. Crédit Agricole Group is a responsible, helpful bank serving 49 million customers, 7.4 million mutual shareholders, and 1.2 million shareholders. Crédit Agricole Group supports its customers in their plans and projectsin France and around the world, through its operations in all segments of the market including insurance, real estate, payment systems, asset management, leasing and factoring, consumer finance, and corporate and investment banking. Crédit Agricole also stands out for its dynamic, innovative corporate social responsibility policy serving the economy. This policy is based on a pragmatic approach that permeates throughout the entire Group and engages all its employees. Its recent inclusion in the Vigeo-NYSE Euronext extra-financial indices is recognition of this engagement.
Show more...Investment focus
- Industry: Energy, Health Care, Software
- Stage:Debt Financing, Seed
- Geography: France, United States, Italy
Investor stats
- Total investments: 184
- Round size: Seed $837k–$6M; Debt Financing $2.1M–$1.3B
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $300M in 2023
Portfolio highlights
- Crelan — Daar wordt u beter van - C'est mieux pour vous
- Bohr Energy — Bohr Energy is an artificial intelligence firm that aims to make the energy market accessible to independent producers.
- Brenus Pharma — Brenus Pharma develops off-the-shelf, next-generation in vivo immunotherapies designed to unlock the immune response against solid tumors.
Floated in 1998, thanks to the local authority "Conseil Régional d’Aquitaine" and the "Caisse des dépôts", our venture, growth and LBO funds (Aquitaine Amorçage, ACI, Aqui-Invest) now benefit from the support of public and private influential shareholders and sponsors.Up to now, AQUITI GESTION has invested in more than 200operations contributing to the creation and development of about 150 companies and thousands of jobs.Currently, ACI and Aqui-Invest manage a portfolio gathering 50 companies which revenues scale from 0 € (early stage) to 30 M€.
Show more...Investment focus
- Industry: Software, Biotechnology, Manufacturing
- Stage:Venture - Series Unknown, Series A, Seed
- Geography: France, United States
Investor stats
- Total investments: 59
- Round size: Seed $170k–$4.1M; Series A $849k–$18M; Venture - Series Unknown $1.8M–$12M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $7.9M in 2010
Portfolio highlights
- Synboli — Synboli is a deep-tech company that combines artificial intelligence and proprietary chemistry technologies to accelerate the discovery and development of novel polymers and advanced materials. Its AI-powered platform predicts polymer properties, designs new molecular structures, and integrates laboratory testing to reduce material developmenttimelines.
- Aquassay — Aquassay assists you with improving the industrial and environmental performance of all your water usage (supply, production, discharge).
- CardNexus — CardNexus provides a digital platform for managing, trading, and selling trading card collections.
IRDI SORIDEC Gestion is a portfolio management company that supports startups, SMEs, and ETIs in the greater South-West of France with equity capital at all stages of development.
Show more...Investment focus
- Industry: Software, Biotechnology, Medical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, Brazil, Singapore
Investor stats
- Total investments: 54
- Round size: Seed $1.7M–$5.8M; Series A $3.7M–$13M; Venture - Series Unknown $1.3M–$12M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Donecle — Automated aircraft inspections by drone for airlines and MRO. Donecle makes aircraft maintenance faster, safer and more reliable. Our unique technology combines 100% automated drone and image analysis algorithms to detect defects, lightning strikes, evaluate paint wear and check placards.
- Nepting — NEPTING is a company specializing in payment solutions and services with the main objective of supporting business in its evolution. Listening to its customers, it brings a skill, a culture, an innovative offer for all existing, emerging and future payment methods.NEPTING equips all types of points of acceptance with its multi-channel andmulti-vendor electronic payment system and its secure solutions in compliance with the standards in force. It is distinguished by its ability to give its customers the many advantages of a single and homogeneous offer for all its sales channels: mPOS, Retail, TPE, Automate, e-commerce ...
- ThIA Santé Mentale —
Wiseed is a crowdfunding platform that enables its users to invest in SMEs and enterprises. The platform offers investments for startups, real-estate firms, social innovation and renewable energy projects, and agriculture firms. It was founded in 2008 by Nicolas Seres and Thomas Merquiol and is based in Toulouse.
Show more...Investment focus
- Industry: Software, Biotechnology, Manufacturing
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, Norway
Investor stats
- Total investments: 34
- Round size: Seed $392k–$3.3M; Series A $1.3M–$7.8M; Venture - Series Unknown $1M–$6.5M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Aéronde — The Aéronde is an innovative electric airship with a toroidal shape (giant donut) of 15 meters in diameter, designed to offer a silent, energy-efficient flight with very low environmental impact. Inflated with approximately 400 m³ of helium, it can carry up to two people and equipment, with a payload of 200 kg .
- Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
- BiPER Therapeutics — BiPER Therapeutics is a biotech company to develop and commercializes novel therapeutics.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 23
- Round size: Seed $2.7M–$3.6M; Series A $1.1M–$35M; Series B $2.2M–$60M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
- VectivBio — Explore Ironwood Pharmaceuticals' commitment to GI health with innovative therapies, patient-focused research, and a vision to improve digestive disease treatment.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
BNP Paribas Développement is the investment arm of BNP Paribas that specializes in SME development. It specializes in second stage, mezzanine, bridge, acquisition, leveraged buyouts, management buyouts, recapitalization, special situations, and privatizations transactions.The firm considers investments in manufacturing, service industries,medicine, electronics, energy, chemistry, new materials, industrial automations, industrial goods and services, transportation, consumer goods, commerce and distribution, buildings and public works, wholesale retail, biotechnology, telecommunications, and information technology sectors.BNP Paribas Développement was established in 1988 and is based in Paris, France.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed
- Geography: France, Germany, The Netherlands
Investor stats
- Total investments: 149
- Round size: Seed $2M–$7M; Series A $3.9M–$24M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Amarris — Amarris Groupe : expertise comptable innovante pour freelances, entrepreneurs, RH et investisseurs immobiliers.
- Proteor — Proteor offers a complete range of high quality products and services to the O&P world, through more than 60 clinics.
- Ostrea — OSTREA is a pioneering company in the creation of high-performance materials based on bio-minerals: seashells.
BNP Paribas provides banking, financing, investment, savings, and protection solutions. The Group's three operational divisions are mobilized to support each type of clientele in their growth and development projects including corporate and institutional banking, commercial, personal banking, investment and protection services. The companyprovide financing and investment services to retail customers, associations, businesses, and corporations.
Show more...Investment focus
- Industry: Financial Services, Information Technology, Software
- Stage:Debt Financing, Post-IPO Debt
- Geography: France, United Kingdom, United States
Investor stats
- Total investments: 309
- Round size: Post-IPO Debt $40M–$2.5B; Debt Financing $8.5M–$1.8B
- Lead/follow: 19% lead, 81% follow
- Last fund: Likely actively investing — fresh fund, raised $799M in 2025
Portfolio highlights
- Proxymity — Announcing our Newest Partnership
- Worldline — Worldline is the platform that provides payments and transactional services.
- Encompass — Award-winning EC360 CDI platform and EC solutions for fast, flawless, and frictionless corporate client identity validation and verification.
Kima Ventures promotes the growth of startups, supporting them in the fastest and most effective ways.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 719
- Round size: Seed $650k–$5.5M; Pre-Seed $591k–$3.8M; Series A $1.2M–$16M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Hoora — Hoora is a mobile gaming platform that offers an instant, scrollable feed of over 200 casual and arcade mini-games playable without downloads or waiting.
- Klaimee — Certify your AI agent. Get guaranteed. Risk evaluation, certification badge, financial guarantee, and liability insurance for AI agents.
- Shiplong — Shiplog gives every customer a live profile and decides the next best action in real time, so you expand, retain and grow revenue from the customers you already have.
Cap Innov’Est is a 36M€ tri-regional fund dedicated to investments in young innovative start-ups. Cap Innov’Est was launched in July 2014 and has already invested in 13 start-ups. Cap Innov’Est is supported by Fonds National d’Amorçage, the 3 Regions Alsace, Bourgogne and Franche-Comté, SAFIDI, caisses d’épargne d’Alsace etBourgogne/Franche-Comté, BNP Paribas et CIFC
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, United States
Investor stats
- Total investments: 18
- Round size: Seed $706k–$2.7M; Series A $8.2M–$8.3M; Venture - Series Unknown $2.5M–$4.5M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $49M in 2014
Portfolio highlights
- VistaCare — "Making Difficult Wounds Easy" : VistaCare is a Breakthrough and non-invasive Medical Device designed for treatment during the critical phases of the wound.
- Opencell Software — Opencell was created in 2015 to leverage an open source telco billing project initiated in 2007 by David Meyer, their current CEO.Their mission is to provide the first agile monetization platform capable of filling the gap between costly and complex legacy billing solutions and the overly simplistic “one size fits all” SaaS solutions that coveronly the most basic requirements.Opencell is now the open source monetization and billing platform with over 40 successful implementations in multiple industries and countries.
- Rhythm Diagnostic Systems — Many of our team have worked together on different projects and in different companies over the last 30-plus years. We are experienced technology, medical, health care and biotech professionals, with long, successful histories in Silicon Valley and elsewhere.
Since 1967, the UI brand embodies a partnership with companies. Actor of the economy, UI has accompanied more than 120 SMEs over the last fifteen years, investing more than 550m € and giving substance to their development projects. Combining experience and corporate culture, UI has established itself as an involved and independent partner, able tocount on its shareholder leaders to favor, independently, the sustainable performance of the SMEs it accompanies.
Show more...Investment focus
- Industry: Manufacturing, Software, Health Care
- Stage:Private Equity, Seed, Series A
- Geography: France, Spain, Canada
Investor stats
- Total investments: 108
- Round size: Seed $1.5M–$5.8M; Series A $3.2M–$33M; Private Equity $3.2M–$49M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $39M in 2021
Portfolio highlights
- FINASENS — FINASENS provides consulting services in financial management and operational support for businesses and other organizations. The company focuses on outsourced chief financial officer services, helping clients manage budgeting, reporting, cash management, and financial planning. FINASENS assists mid-sized and small companies that need structuredfinancial direction without building a full internal finance department. Its consultants also contribute to operational improvement projects related to finance processes and management control. FINASENS engages on a recurring or project basis depending on client needs and scope of work.
- Brenus Pharma — Brenus Pharma develops off-the-shelf, next-generation in vivo immunotherapies designed to unlock the immune response against solid tumors.
- B Capital Partners — B Capital Partners is a financial services firm offering investment advisory solutions with a focus on infrastructure and clean energy.
XAnge is a Franco-German team of venture capital investors that manages €450 million and invests in digital, deeptech, and impact startups.It is the innovation brand of the Siparex group, a major player in French private equity. XAnge is a key European investor in early-stage startups and is looking for game-changing startups and entrepreneurswho rock the code[s].The Paris, Ile-de-France-located company was founded in 2004.
Show more...Investment focus
- Industry: Software, SaaS, E-Commerce
- Stage:Series A, Seed, Series B
- Geography: France, Germany, Belgium
Investor stats
- Total investments: 237
- Round size: Seed $1.1M–$8M; Series A $3M–$22M; Series B $6.6M–$75M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $261M in 2021
Portfolio highlights
- ELDIM — Eldim proposes photometric and calorimetric products of instrumentation allowing to qualify the ergonomic parameters and the quality of the image of the flat screens. Its customers (manufacturers of components or sreen-Sharp, Sony, Samsung, -or integrators-IBM, Apple, Valeo, Honeywell, Nokia, Motorola-) are mainly foreigns.
- Skello — Skello is the The AI HR solution for frontline teams. HR tools were designed for offices, yet 55% of the workforce works on their feet and deserves technology designed for the field. Our mission is to improve their daily lives. For managers and HR directors, Skello offers seamless management from hiring to the payslip: our AI automatestime-consuming tasks so they can anticipate and supervise while maintaining full control. For teams, Skello guarantees a transparent and collaborative experience from their very first day. In July 2026, we reached a major milestone with the announcement of €200 million in funding to accelerate our development. After 10 years spent listening to our customers, this new chapter solidifies our conviction: technology must assist and facilitate work, without ever replacing humans. Our ambition is to be the go-to AI HR management solution for all frontline teams in Europe.
- Aerospacelab — Aerospacelab makes access to space simple. By combining our satellite platforms with mission payloads, Aerospacelab is able to deliver end-to-end satellite solutions tailored to meet your business needs.
Octalfa is a France-based venture capital firm that offers a range of financial services.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Venture - Series Unknown
- Geography: France
Investor stats
- Total investments: 20
- Round size: Seed $658k–$4.6M; Venture - Series Unknown $1.9M–$2.4M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Kimialys — Kimialys provides a patented and disruptive surface chemistry for biosensors, enabling the development of innovative rapid diagnostic assays.
- Sirius NeoSight — Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it.
- Ventuno Biotech — Our biotech company is at the forefront of developing innovative cancer therapies. Our approach centers on unlocking the potential of the immune system to
Demeter is a major player in venture capital and private equity for the energy and ecological transition. They invest from 500 K€ to 30 M€ to support companies at all stages of their development: innovative startups, high growth SMEs and infrastructure projects.
Show more...Investment focus
- Industry: Manufacturing, Software, AgTech
- Stage:Seed, Series A
- Geography: France, Germany, Slovenia
Investor stats
- Total investments: 100
- Round size: Seed $1.5M–$6M; Series A $6.4M–$27M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $53M in 2018
Portfolio highlights
- Jay&Joy — Jay&Joy is the first plant-based creamery in France engaged in manufacturing alternatives to cheese made from almond milk and cashew nuts.
- Quideos — Quideos is an agriculture based platform that ensures secured purchase and sale of agricultural raw materials.
- Phase One Lionheart — VER GEO LIO GmbH ("PhaseOneCo") is an indirect subsidiary of Vulcan Energy Resources Limited.
Galia Gestion is a private equity and venture capital firm. GALIA Gestion is a “management company” approved by the AMF, with majority shareholder Alliance Entreprendre.
Show more...Investment focus
- Industry: Software, Manufacturing, Biotechnology
- Stage:Venture - Series Unknown, Series A
- Geography: France, United States
Investor stats
- Total investments: 55
- Round size: Series A $849k–$7.2M; Venture - Series Unknown $1M–$12M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $26M in 2013
Portfolio highlights
- Wizaly — Wizaly's ambition is to help advertisers understand the impact of their online & offline marketing channels across all conversions, helping clients improve the ROI of their marketing budgets by up to 30%.The Wizaly platform applies its algorithmic attribution technology to provide a holistic and unbiased vision of campaigns performancestogether with actionable optimization recommendations.
- Agenium — Agenium offers career perspectives in an international and tech environment. They offer this through the specific expertise of their business units. They offer solutions to the business and of the defense, industry, and space sectors.
- Germitec SAS — Germitec is a world leader in UV-C high-level disinfection. Fast, safe, chemical-free, one-button UV-C high-level disinfection for ultrasound probes.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!IRDI Gestion aims to participate in the economic growth and job creation in their regions. For this, their teams create a real partnership with the companies they accompany, based on a relationship of trust and proximity.IRDI Gestion currently manages €150 million and has financial tools able to accompany the Southwest SMEs in the creationphase, development or transmission, with intervention tickets from equity € 100000 to € 5000000.Precursor of regional investment capital of the Southwest, with a presence of over 35 years, the IRDI Group consists of 3 SCR:- IRDI, created in 1981 to foster industrial growth companies based in the South West of France- MPcroissance, created in 1996 to assist small businesses in Midi-Pyrénées- IRDInov, created in 2012 under the leadership of the National Seed Fund (under the PIA) to fund the initiation of innovative companiesIn 2015, the management company IRDI Gestion, approved by the AMF, was formed to structure the group and bring new development projects.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed
- Geography: France
Investor stats
- Total investments: 46
- Round size: Seed $757k–$9.2M; Series A $1.6M–$23M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- FineHeart — Our mission is to address the unmet need of patients with sever heart failure
- REEV — REEV motorizes medical orthoses to help millions of people affected by gait disorders to walk, stand, sit and climb stairs with greater ease every day.
- Starfish Bioscience — STARFISH Bioscience focuses on the creation and development of microbiological solutions for agriculture and vineyards. Our objective is to regenerate soils by restoring their microbiomes, increasing sustainability and productivity while minimizing environmental impact. We are dedicated to improving humanity's well-being and preserving theearth by inventing technologies that address the future difficulties of global agriculture.
Anaxago is a brand new crowdfunding platform dedicated to innovative companies. Anaxago aims at changing the traditional equity capital investment model. Their goal is to forget about the capitalistic-only and go for a truly sharing and participative investment model. Thanks to Anaxago, entrepreneurs can benefit from the financial support oftheir investors but also learn from the shareholders' experience, expertise and network. Each investor can take an active part to the company life and so be a part of a lively entrepreneurial adventure.They offer a small range of companies each month to their investors community. Startups and small companies are chosen with good care and have to go through a whole process of financial analysis. They also prefer to select companies with a real innovative value added. With Anaxago, young and small companies can find funding and support to grow and develop. They give them a chance to be the actors of tomorrow's growth and reboost their economy.Since its launch, Anaxago gathered 100 000 members and invested more than 130M€ funding more than 200 businesses.
Show more...Investment focus
- Industry: Biotechnology, SaaS, Software
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, Belgium, Cameroon
Investor stats
- Total investments: 46
- Round size: Seed $620k–$2.7M; Series A $1.3M–$13M; Venture - Series Unknown $1.5M–$3.3M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $11M in 2019
Portfolio highlights
- Posos — Posos is a clinical support platform optimizing healthcare professionals’ decisions at every step of the patient journey thanks to an AI-based cross-referencing search engine. Posos allows healthcare professionals to conduct simultaneous research on several drugs and to contextualize answers based on patient data
- Check & Visit — In Brittany, in Rennes Check & Visit was born from the desire to help the owners of the whole world to realize the conditions of their apartment. In France each year, there are over 3,400,000 inventories made. For the 2,500,000 owners, which they are part of it is not always easy to make the inventory of his apartment. Whether due to lack ofavailability, legal knowledge, or the reliability of paper status reports. The inventory quickly becomes a tedious and time-consuming task that any owner would like to do without.
- PEP-Therapy — PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 82
- Round size: Seed $137k–$6M; Series A $3.6M–$16M; Venture - Series Unknown $2M–$16M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
High Tech, Low Carbon: crafting tomorrow, today. We finance innovation to make tomorrow happen today. Starquest is a Montefiore Company.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, Singapore, United States
Investor stats
- Total investments: 116
- Round size: Seed $291k–$2.5M; Series A $1.2M–$11M; Venture - Series Unknown $448k–$20M
- Lead/follow: 20% lead, 80% follow
- Last fund: Likely actively investing — fresh fund, raised $200k in 2026
Portfolio highlights
- Heliup — Heliup is a company that creates and manufactures solar systems for huge building roofs for commercial and industrial buildings.
- Cailabs — Cailabs is a global leader in free-space optical communications. Its dual-use Optical Ground Stations (OGS) are deployed worldwide by leading satellite operators and agencies such as SES, ESA and Contec. The company is among the very few globally to have demonstrated satellite-to-ground links fully compliant with the US Space Development Agency(SDA) standard, confirming its unique technological position.It also plays a central role in European sovereignty/defense programs such as Keraunos, developing secure OGS for next-generation optical satellite links.Founded in 2013, Cailabs has raised over €100M and grown to 170 employees (as of Dec 2025). Cailabs has a global presence with 3 offices : its HQ based in Rennes (Brittany, France), 1 office in Paris (France) and 1 office in Washington DC (Arlington, VA).
- Eurodia — Eurodia is a designer, manufacturer, and assembler of industrial solutions for the purification of fluids. They provide liquid purification industrial processes combining electrodialysis, chromatography, ion exchange systems, and membrane filtration. They provide these tools for the dairy and cheese industries, the sugar and wine industries, andthe field of energy and ecological transition. They provide electrodialysis technology, bipolar membrane electrodialysis, membrane filtration, and much more.
Caisse d’Epargne is a cooperative bank that supports all economic players. It shares its values of social responsibility and humanism with its member customers. It is committed to the heart of the regions, the 15 regional savings banks are involved on a daily basis in their clients' projects and provide them with tailor-made solutions.Ithas now had 4.8 million members and 20.6 million customers, managed by 4,182 bank branches and the My Online Banker branch.It was created in 1818 and is headquartered in Paris, France.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Debt Financing, Seed
- Geography: France
Investor stats
- Total investments: 51
- Round size: Seed $400k–$4.4M; Debt Financing $445k–$169M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Calicéo — Calicéo operates as a family group of aquatic fitness and beauty-massage spaces.
- Leanspace — Today, space organizations need to build and manage increasingly complex ground software infrastructures: to design, integrate and operate their assets. To do so, they can rely on off-the-shelf systems (COTS) but lose control over their tools, or build everything from scratch which is slow and consumes lots of resources.Leanspace brings a new wayto build space software. We provide all the generic functions, easily consumable as-a-service, via APIs. The platform enables organizations to build all their systems in-house, but only developing the functionalities they need. This drastically reduces time & costs, keeps them in control, and boosts competitiveness.Leanspace-powered systems are integrated, collaborative and digital. Don’t reinvent the wheel, transform your business!
- Miura Simulation — Miura helps engineers take control of their data, connect tools, reduce vendor friction, and lay the foundation for scalable AI.
Finovam Gestion is an investment company approved by the AMF which takes minority stakes in innovative SMEs with high growth potential.The company, which manages €50M, invests in companies that have developed innovative offers in the following target sectors: Information and Communication Technology, Health and Biotechnologies, Agro-resources andEcotechnologies.Finovam Gestion has built solid relationships with the ecosystem of entrepreneurship (Industrials, Poles of Competitiveness, Incubators, Accelerators, Universities, and Research Centers) in all the sectors that we target in order to be able to source and do emerge the best companies.Among our investors (LPs), we can count BPI France, manufacturers (ADEO, LESAFFRE, TEREOS), banks (BNP Paribas, Caisse d´Epargne, Crédit Agricole) and the Haut de France and Grand-Est regions.
Show more...Investment focus
- Industry: Software, Information Technology, Medical
- Stage:Seed, Series A
- Geography: France, United States
Investor stats
- Total investments: 44
- Round size: Seed $513k–$3.4M; Series A $530k–$18M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Pikkopay — Pikkopay provides a mobile payment solution that transforms customer smartphones into cash registers. Customers can scan items, pay, and go, eliminating the need for traditional checkout lines. The service aims to streamline the shopping experience and increase user retention rates. Pikkopay is designed to save time for both customers andretailers, offering a hassle-free shopping experience.
- StemInov — StemInov is developing a stem cell therapy for inflammatory diseases with a first focus on critical care: septic shock and ARDS
- Lattice Medical — Lattice Medical also provides solutions for improving tissue engineering and regenerative medicine using 3D-printed bio-resorbable scaffolds.
Sham Innovation Sante is an innovation capital vehicle controlled and held by Sham, a mutual insurer specialized in risk management for health care, social welfare and community health organizations. Advised by Turenne Capital, Sham Innovation Sante's mission is to support innovative businesses in the health care sector through the growth anddevelopment phases of their life cycle.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Medical
- Stage:Series B, Series A, Venture - Series Unknown
- Geography: France
Investor stats
- Total investments: 16
- Round size: Series A $6.1M–$74M; Series B $10M–$80M; Venture - Series Unknown $1.8M–$12M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Cairdac — Cairdac is a manufacturer of autonomous leadless pacing transcatheter system capable of powering the device with no battery-life limitation.
- Therapixel — Therapixel is one of the leading French software companies specializing in artificial intelligence applied to medical imaging.
- Germitec SAS — Germitec is a world leader in UV-C high-level disinfection. Fast, safe, chemical-free, one-button UV-C high-level disinfection for ultrasound probes.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
InnoBio is a French venture capital fund of €140 million, managed by CDC Enterprises (www.cdcentreprises.fr) and for 37 per cent subscribed by the FSI and leading international pharmaceutical companies in France. The fund makes direct equity and quasi-equity investments in companies that provide innovative technological products and services in thehealthcare market.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: France, United States
Investor stats
- Total investments: 14
- Round size: Series A $16M–$21M; Series B $14M–$21M; Series C $18M–$26M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Millendo Therapeutics — Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.
- Diotheris — Diotheris develops bacterial therapies of the human skin and mucosal microbiome intended to protect against pathogenic bacteria. The company's products are based on live bacteria includes NASOFLORE which targets Staphylococcus aureus, enabling the prevention of infections due to major pathogen and protecting patients against biologicalthreats.
- AlgoTherapeutix — AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain.
Venture capital for companies developing innovative therapeutics.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series A, Series B, Series C
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 36
- Round size: Series A $12M–$123M; Series B $7.1M–$100M; Series C $22M–$125M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $205M in 2020
Portfolio highlights
- NovaGo Therapeutics — NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. A strategic partnership with Neurimmune provides access to a unique class of human-derived antibodies with exceptional therapeutic propertiesgenerated through their Reverse Translational Medicine™ (RTM™) technology platform.
- Tavo Biotherapeutics — Tavo Biotherapeutics is a biotech company that develops injection therapies for eye diseases.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!M Capital is an independent investment company with +€500m AuM. A unique hub where entrepreneurs can have an equity finance and quasi-equity as well as a permanent support to accelerate their growth. In 2020, M Capital has funded over 200 French companies.
Show more...Investment focus
- Industry: Health Care, Software, Food and Beverage
- Stage:Venture - Series Unknown, Seed
- Geography: France, United States, Canada
Investor stats
- Total investments: 113
- Round size: Seed $1.1M–$5.4M; Venture - Series Unknown $1.2M–$5.6M
- Lead/follow: 56% lead, 44% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Haiku — L'IA et la data au service des du droit
- The Sanctuary Group — The Sanctuary Group provides aqua-cycling, indoor cycling, boxing bootcamp, yoga, dance cardio, HIIT workouts, and kids’ swim classes.
- Ascendance — Sustainable flight solutions for today & tomorrow... because cleaner aviation can't wait. With Ascendance, Fly quieter, cleaner, further.
Crédit Mutuel Innovation is the evergreen venture capital entity of Crédit Mutuel Equity (€3.5 billion in capital). We invest €1-20M in life science, digital and deeptech companies from seed to growth stages.We help bold and ambitious entrepreneurs to develop their strong growth potential with our worldwide enterprise ecosystem (our 350+portfolio companies, our abroad subsidiaries, 150+ largest global corporates and the best-in-class experts). Because it takes more than 5 years to build a Unicorn, we invest our own equity and ensure durable partnerships with visionary leaders.Today, the 350 companies in which we have invested generate a cumulative annual turnover of €50bn and create more than 250,000 jobs.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: France, United States, Belgium
Investor stats
- Total investments: 109
- Round size: Series A $3.4M–$26M; Series B $7.2M–$43M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- e-peas — Discover e-peas, pioneer of the Ambient IoT concept since 2014, which offers the most efficient energy harvesting pmics on the market to make your devices more energy self-sufficient: AEMs.
- Ever Dye — A new standard for dyes. Naturally made, carbon emissions reducing, water protecting.
- Standing Ovation — Animal-free dairy cheese
EMERTEC’s experienced investment team has developed proven track record and has been able to develop close ties with major industrial players, many of them also being investors in their funds.These close ties are extremely valuable as to understand medium and long-term requirements of major order placers and high-level commercial opportunities.This brings visibility and confidence for entrepreneurs as well as for its investors.Their objective is to create value by turning ground-breaking technological innovations into commercial and financial successful companies.
Show more...Investment focus
- Industry: Electronics, Energy, Biotechnology
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: France, Canada, Switzerland
Investor stats
- Total investments: 28
- Round size: Seed $1.5M–$3.3M; Series A $1.4M–$6.8M; Venture - Series Unknown $1.2M–$6M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — raised $78M in 2008
Portfolio highlights
- SENCROP — Sencrop is an ag-tech startup that offers an in-field data-based platform to empower farmers to make better decisions in their daily agricultural activities. Sencrop designs and sells connected weather forecast solutions for farmers to measure rain, hygrometry, and wind speed. The sensors are cheap, robust, movable, and easy to use, making moreefficient and sustainable farming possible
- Osmia — Osmia SAS provides crop pollination services to improve yield and quality of agricultural production. Osmia intervenes in the context of specific problems on entomophilous or anemophilic pollination. Methodological approach and experience enables the company to find relevant solutions. It offers pollination studies and services for pre-base, baseor multiplication seeds. It also offers simple and efficient pollination services for arboriculture and optimize the yields and the quality of the productions of fruit trees.Osmia SAS was founded on 2014 and is headquartered in France.
- MESA Imaging — MESA Imaging is focusing on the development and production of 3D time-of-flight cameras.
CEA Investissement (SA), founded (as CEA Valorisation) in 1999, is a subsidiary of the CEA, a major player in technological research, development and innovation. The central mission of CEA Valorisation is to create economic value based on technological innovations. To fulfill this mission, they have developed two main activities: Investmentin seed capital in innovative start-ups / start-ups active in the technology areas of CEA. The Licensing of advising companies and public laboratories of innovation in creative strategy development and marketing rights to patent or know-how belonging to the CEA, other research organizations or innovative companies. In addition, CEA contributes to the financing of national investment in seed technology (activity "Fund of Funds"), this activity is developed through particular Emertec management and funds managed by this company (FCPR Emertec 2 Emertec Energy and Environment), the FCPR managed by ACE Security Management SA, an investment company in seed priming Minatec SAS. Their areas of technological expertise are mainly micro-and nanotechnology, health technologies, the New Technologies for Information and Communication (NTIC), advanced materials and technologies for energy.
Show more...Investment focus
- Industry: Manufacturing, Energy, Biotechnology
- Stage:Seed, Series A
- Geography: France, Canada, United States
Investor stats
- Total investments: 45
- Round size: Seed $796k–$21M; Series A $1.4M–$13M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — raised $50M in 2013
Portfolio highlights
- iNGage — iNGage is a manufacturer of high-performance inertial MEMS navigation sensors for high-volume autonomous mobility markets
- STELLARIA — Stellaria is a 200 MWe molten salt reactor with 20-year autonomy, delivering safe, sustainable nuclear power without refueling.
- STELLARIA — Stellaria is reimagining sustainable rapid neutron nuclear energy.
Paca Investissement is specializes in investing in startups and developmental stages. The fund invests in the Provence-Alpes-Côte d'Azur (PACA) region.
Show more...Investment focus
- Industry: Software, Internet, Manufacturing
- Stage:Seed, Venture - Series Unknown
- Geography: France
Investor stats
- Total investments: 73
- Round size: Seed $325k–$1.7M; Venture - Series Unknown $1.1M–$5.7M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- GANGZ — Gangz is the first digital platform for talent recruitment: Models, hosts, extras and actors.
- SailEazy — The SailEazy community offers all sailing enthusiasts the choice of freedom. A shared professional fleet, bases between the Atlantic and the Mediterranean ... discover a disruptive and innovative way of navigation. Throughout the year, 7 days / 7 and 24 hours a day, you can book and discover the high-performance sailboats of a professionalfleet, entirely managed by SailEazy. Subscriber, or punctual browser, autonomous or not, you have the choice. You freely determine your niche of reservation, without constraint time or duration, you choose your base of departure and your sailboat, according to your program (short exit, cruise, regatta, coastal, wide ...). Hourly pricing includes a 360 ° service keychain beyond the cost of the lease, including insurance, fuel, cleaning and equipment. Compulsive veiled, expert or contemplative, all members of the community have their way of navigating.
- C4Diagnostics — Dana69 adalah tempat penyedia link login game online yang bisa di mainkan dengan menggunakan smartphone android dan iphone dan bisa melakukan top up slot dana 10k atau slot deposit dana 10k selalu online 24 jam.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 301
- Round size: Seed $1.2M–$11M; Series A $2.1M–$18M; Series B $3.9M–$45M
- Lead/follow: 15% lead, 85% follow
- Last fund: Likely still investing — raised $61M in 2022
Portfolio highlights
- Axelera AI — Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
- Atana Elements — Atana is accelerating the exploration and development of flowing critical minerals and industrial gases. Atana uses a proprietary tech stack to identify and mature mineral resources quickly and effectively.
Nord France Amorçage is a regional co-investment fund, exclusively supported by the Hauts-de-France Region. This seed fund has been involved since 2013 in financing innovative businesses that create jobs and add value to the region. In 6 years, NFA has more than 50 participants spread across the region.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, United States
Investor stats
- Total investments: 47
- Round size: Seed $421k–$2.8M; Series A $1.1M–$25M; Venture - Series Unknown $1.4M–$8.6M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Ensweet — Ensweet is a telemedicine platform intended to offer telerehabilitation services to patients. They offer equipment so that everyone can exercise whenever possible, enabling patients to have accessible rehabilitation.
- Hemerion — Advancing cancer therapies with Hemerion Therapeutics' innovative technology to fight brain cancer and glioblastoma.
- Lattice Medical — Lattice Medical also provides solutions for improving tissue engineering and regenerative medicine using 3D-printed bio-resorbable scaffolds.
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Private Equity, Series A
- Geography: France, United States, Germany
Investor stats
- Total investments: 187
- Round size: Series A $7M–$83M; Series B $14M–$83M; Private Equity $112M–$237M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fresh fund, raised $491M in 2026
Portfolio highlights
- Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
- Inventiva Pharma — Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
- Rivermark Medical — Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects.
Newfund is a $300M entrepreneurial VC firm dedicated to pre-seed and seed investments in France and North America, in companies driving global change. The company is always looking for founders who are driven to realize a vision that will significantly alter the world in which we live. In order to appreciate what entrepreneurs are creating andutilize their strengths, Newfund aims to comprehend entrepreneurs as unique individuals.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Series A
- Geography: France, United States, Canada
Investor stats
- Total investments: 199
- Round size: Seed $1.1M–$5M; Series A $1.6M–$15M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $65M in 2023
Portfolio highlights
- Zinier — Zinier builds customizable field service management software that enables you to create the field service workflows you need, without touching a line of code.
- Moodwork — Moodwork provides a digital platform for workplace mental health that combines AI with human expertise to support employees through assessments, guidance, and access to professional resources. The platform also delivers anonymized workforce insights, enabling organizations to monitor mental health trends, protect employee privacy, and supportinformed workplace decisions.
- AI-Stroke — Developer of an artificial intelligence-powered mobile application designed to assist in pre-CT/MRI stroke diagnostics. The company offers a platform that guides first responders and patients through relevant exercises for stroke detection, captures and analyzes video data, and leverages the world's largest proprietary stroke patientvideo dataset (20,000 videos and 6 million images), enabling patients with a diagnosis and outcomes by reducing delays in treatment for stroke, increasing the number of treatment procedures, and recuding the rehab costs.
HCVC is an early-stage Venture Capital firm backing hardtech companies worldwide. Beyond its fund, HCVC supports hardtech founders through Hardware Club, a selective global community of 500+ startups with dedicated resources, partnerships and events.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Robotics
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, France, United Kingdom
Investor stats
- Total investments: 96
- Round size: Seed $920k–$11M; Pre-Seed $1.4M–$5.2M; Series A $5.2M–$30M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- NavierAI — Navier AI CFD platform allows aerospace and mechanical engineers to design high-performance machines with ease.
- Chiral — Next-generation electronics with nanomaterials
- Karavela — Karavela is a company developing a "foundation model" of the human brain using large-scale brain imaging data (like MRI) and AI.
Biotech Investor funding in France at a glance
Stats across 1.5k deals from 1.3k investors.
Access all 1265 investors in France Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in France investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1265 investors investing in France Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!